Analystreport

Nabriva Therapeutics (NASDAQ: NBRV) was given a new $16.00 price target on by analysts at Cantor Fitzgerald. They now have a "buy" rating on the stock.

Nabriva Therapeutics plc - Ordinary Shares  (NBRV) 
Last nabriva therapeutics plc - ordinary shares earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.nabriva.com/investor-relations